Kornitzer Capital Management’s Clearside Biomedical CLSD Stock Holding History

Kornitzer Capital Management’s Portfolio CLSD Stock Details CLSD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-6,187	Closed	-$571K	–	478
2018 Q3	$571K	Hold	6,187	–	–	0.01%	424
2018 Q2	$992K	Buy	6,187 +1,187	+24%	+$200K	0.02%	378
2018 Q1	$805K	Hold	5,000	–	–	0.01%	394
2017 Q4	$525K	Hold	5,000	–	–	0.01%	428
2017 Q3	$655K	Hold	5,000	–	–	0.01%	408
2017 Q2	$683K	Hold	5,000	–	–	0.01%	414
2017 Q1	$595K	Hold	5,000	–	–	0.01%	416
2016 Q4	$670K	Buy	+5,000	New	+$1.26M	0.01%	403

Other funds holding CLSD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kornitzer Capital Management's CLSD Position: Q4 2018 in Review

Kornitzer Capital Management sold out of Clearside Biomedical (CLSD) in Q4 2018, closing a stake of 6,187 shares — an estimated $571K sold.

Kornitzer Capital Management first reported a position in CLSD in Q4 2016 and held it in 8 quarters. The position peaked at $992K in Q2 2018. 69 funds tracked by Wall St. Rank hold CLSD as of Q4 2018.

Kornitzer Capital Management reported no remaining Clearside Biomedical position as of Q4 2018 after selling out during the quarter.
Kornitzer Capital Management sold 6,187 Clearside Biomedical shares in Q4 2018, an estimated $571K.
Kornitzer Capital Management first reported a position in Clearside Biomedical in Q4 2016 and held it in 8 quarters.
Kornitzer Capital Management's Clearside Biomedical position peaked at $992K in Q2 2018.
69 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2018.

Based on Kornitzer Capital Management's 13F filing for Q4 2018, filed 31 Jan 2019.